Abstract
Lower extremity fractures in men with spinal cord injury (SCI) are a major problem.
The use of thiazide diuretics, a simple and safe intervention, may be effective in
reducing the risk of fracture in patients with traumatic SCI. Furthermore, thiazide
diuretics have an added benefit of reducing kidney stone formation.
Keywords
List of abbreviations:
BMD (bone mass density), SCI (spinal cord injury)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Archives of Physical Medicine and RehabilitationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Mortality following lower extremity fractures in men with spinal cord injury.J Bone Miner Res. 2014; 29: 432-439
- An effective oral vitamin D replacement therapy in persons with spinal cord injury.J Spinal Cord Med. 2011; 34: 455-460
- Prevention of bone loss in paraplegics over 2 years with alendronate.J Bone Miner Res. 2004; 19: 1067-1074
- Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal injury.Calcif Tissue Int. 2007; 80: 316-322
- Effect of pamidronate administration on bone in patients with acute spinal cord injury.J Rehabil Res Dev. 2005; 42: 305-313
- Alendronate increases bone density in chronic spinal cord injury: a case report.Arch Phys Med Rehabil. 2002; 83: 139-140
- Effect of alendronate on bone density in spinal cord injury patients: a pilot study.Spinal Cord. 2005; 43: 341-348
- Non-pharmacological treatment and prevention of bone loss after spinal cord injury: a systematic review.Spinal Cord. 2009; 47: 508-518
- Thiazide use is associated with reduced risk for incident lower extremity fractures in men with spinal cord injury.Arch Phys Med Rehabil. 2014; 95: 1015-1021
- Thiazide diuretic agents and the incidence of hip fracture.N Engl J Med. 1990; 322: 286-290
- Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group.Ann Intern Med. 1993; 118: 666-673
- Risk factors for osteoporotic fractures in elderly men.Am J Epidemiol. 1996; 144: 255-263
- Role of drugs in fractures of the femoral neck.Br Med J (Clin Res Ed). 1986; 292: 861-863
- Long-term use of thiazide diuretics and risk of hip fracture.Lancet. 1989; 1: 687-690
- Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study.JAMA. 1991; 265: 370-373
- Current use of thiazide diuretics and prevention of femur fractures.J Clin Epidemiol. 1996; 49: 115-119
- Risk factors for hip fracture in men.Am J Epidemiol. 1997; 145: 786-793
- Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults.Ann Intern Med. 2000; 133: 516-526
- Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones.Urolithiasis. 2013; 41: 315-322
- Secondary health complications in an aging Canadian spinal cord injury sample.Am J Phys Med Rehabil. 2008; 87: 545-555
- Current trend and risk factors for kidney stones in persons with spinal cord injury: a longitudinal study.Spinal Cord. 2000; 38: 346-353
- Changing composition of renal calculi in patients with neurogenic bladder.J Urol. 2006; 175: 1716-1719
- Changing composition of renal calculi in patients with musculoskeletal anomalies.J Endourol. 2011; 25: 1519-1523
- Silent hydronephrosis/pyonephrosis due to upper urinary tract calculi in spinal cord injury patients.Spinal Cord. 2000; 38: 661-668
- Challenge of percutaneous nephrolithotomy in patients with spinal neuropathy.Int J Urol. 2006; 13: 874-879
Article info
Footnotes
Disclosures: Lyles reports research support from Novartis, Amgen, and Kirin Pharmaceuticals. He is a consultant for Novartis, Amgen, and UCB. He is the cofounder and equity owner of BisCardia Inc; Faculty Connection LLC. He is (1) co-inventor of U.S. patent application: Methods for Preventing or Reducing Secondary Fractures After Hip Fracture (no. 20050272707); (2) inventor of U.S. patent application: Medication Kits and Formulations for Preventing, Treating, or Reducing Secondary Fractures After Previous Fracture (no. 12532285); (3) co-inventor of U.S. patent application: Bisphosphonate Compositions and Methods for Treating Heart Failure (no. 20104717); and (4) co-inventor of U.S. patent application: Bisphosphonate Compositions and Methods for Treating and/or Reducing Cardiac Dysfunction (no. 61/560, 328). Nassaralla has nothing to disclose.
Identification
Copyright
© 2014 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
